Completed
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
NCT00759174
- Conditions
- Cardiovascular Diseases, Cranial Nerve Diseases, Eye Diseases, +4 more
- Locations
-
- Pfizer Investigational Site Birmingham, Alabama, United States
- Pfizer Investigational Site Mobile, Alabama, United States
- Pfizer Investigational Site Anchorage, Alaska, United States
- Pfizer Investigational Site Little Rock, Arkansas, United States